Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495195 · ClinicalTrials.gov registry record · Phase 2
Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior
A Phase 2 study of Cocaine Use Disorders, sponsored by Midwest Biomedical Research Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01495195 is a Phase 2 study of Cocaine Use Disorders that has completed, run by Midwest Biomedical Research Foundation. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01495195, a Phase 2 study of Cocaine Use Disorders, has completed, sponsored by Midwest Biomedical Research Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
No medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Donepezil is a medication that is currently prescribed for Alzheimer's disease, and selegiline is a medication used for treatment of Parkinson's Disease. Both of these medications can decrease the amount of cocaine injections that laboratory animals choose to inject by vein. This project will determine if combined treatment with donepezil and selegiline can also decrease cocaine-motivated behavior for human subjects in a laboratory setting.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Selegiline
- DRUG High-dose donepezil
- DRUG Low-dose donepezil
Study Locations (1)
Missouri
- Kansas City VA Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01495195
The ClinicalTrials.gov registry entry for NCT01495195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Midwest Biomedical Research Foundation, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine Use Disorders appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01495195 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01495195 about?
NCT01495195 is a clinical study titled "Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior". No medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Donepezil is a medication that is currently prescribed for Alzheimer's disease, and selegiline is a medication used for treatment of Parkinson's Di...
What is the current status of trial NCT01495195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2012-02. Estimated completion is 2013-05.
What conditions does trial NCT01495195 study?
This clinical trial studies the following conditions: Cocaine Use Disorders.
What interventions are being tested in trial NCT01495195?
The interventions under investigation include: Placebo (DRUG), Selegiline (DRUG), High-dose donepezil (DRUG), Low-dose donepezil (DRUG).
Who is sponsoring clinical trial NCT01495195?
This trial is sponsored by Midwest Biomedical Research Foundation, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01495195 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.